[Systemic mycoses: therapy with a new antifungal drug diflucan].
A new antifungal drug of systemic action diflucan (Pfizer, USA) has been tried in 10 patients (mean age 35.9 + (-)3.7 years) with various disseminated mycoses. The drug was used in a daily dose 200 mg intravenously or orally for 23.6 + (-)3.3 days. The response was achieved in all the patients with disseminated mycoses caused by yeast fulgi. Side effects were not registered.
Barantsevich
E P
EP
NIO of Deep Mycoses, Saint-Petersberg.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D016919:Meningitis, Cryptococcal / Q000188:drug therapy* / Q000382:microbiology; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D015725:Fluconazole